Enovis Corporation

NYSE (USD): Enovis Corporation (ENOV)

Last Price

44.84

Today's Change

+0.40 (0.90%)

Day's Change

43.77 - 44.85

Trading Volume

514,861

Overview

Market Cap

2 Billion

Shares Outstanding

54 Million

Avg Volume

591,265

Avg Price (50 Days)

49.26

Avg Price (200 Days)

53.61

PE Ratio

-23.60

EPS

-1.90

Earnings Announcement

01-Aug-2024

Previous Close

44.44

Open

44.61

Day's Range

43.81 - 44.84

Year Range

43.04 - 66.14

Trading Volume

458,293

Price Change Highlight

1 Day Change

0.90%

5 Day Change

-0.88%

1 Month Change

-3.26%

3 Month Change

-26.06%

6 Month Change

-20.23%

Ytd Change

-19.12%

1 Year Change

-30.24%

3 Year Change

-43.11%

5 Year Change

-2.54%

10 Year Change

-64.77%

Max Change

24.06%

News and Blogs

No result.

Company Profile

Sector: Industrials - Industrials

Industry: Specialty Industrial Machinery

Description:

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment